您的当前位置:首页 > 行业数据 > BL-B01D1:2L+非经典突变NSCLC的疗效(Her2突变人群非头对头对比德曲妥珠单抗)
图片属性
图片格式:PNG 图片大小:76KB 图片尺寸:1819*495
同报告图片
 / 4
BL-B01D1:2L+非经典突变NSCLC的疗效(Her2突变人群非头对头对比德曲妥珠单抗)_第1页
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
BL-B01D1:2L+非经典突变NSCLC的疗效(Her2突变人群非头对头对比德曲妥珠单抗)_第2页
BL-B01D1:2L+非经典突变NSCLC的疗效(Her2突变人群非头对头对比德曲妥珠单抗)_第3页
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
BL-B01D1:2L+非经典突变NSCLC的疗效(Her2突变人群非头对头对比德曲妥珠单抗)_第4页
BL-B01D1:2L+非经典突变NSCLC的疗效(Her2突变人群非头对头对比德曲妥珠单抗)_第5页
所属报告: 医药健康行业专题研究:2025 ASCO (一)国产双抗ADC剑指FICBIC有望成难治肿瘤新解-250602(14页).pdf
打包全文图表

相关数据

客服
商务合作
小程序
服务号
折叠